Cargando…

Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy

BACKGROUND: Glycemic control is suboptimal in many individuals with type 2 diabetes. Although use of flash continuous glucose monitoring (CGM) has demonstrated A1C reductions in patients with type 2 diabetes treated with a multiple daily injection or insulin pump therapy regimen, the glycemic benefi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wright, Eugene E., Kerr, Matthew S.D., Reyes, Ignacio J., Nabutovsky, Yelena, Miller, Eden
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Feature Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178717/ https://www.ncbi.nlm.nih.gov/pubmed/34149259 http://dx.doi.org/10.2337/ds20-0069

Ejemplares similares

Using Flash Continuous Glucose Monitoring in Primary Practice
por: Hirsch, Irl B., et al.
Publicado: (2019)

Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin
por: Santeusanio, Andrew D., et al.
Publicado: (2018)

Association Between Change in A1C and Use of Professional Continuous Glucose Monitoring in Adults With Type 2 Diabetes on Noninsulin Therapies: A Real-World Evidence Study
por: Nemlekar, Poorva M., et al.
Publicado: (2023)

Using Continuous Glucose Monitoring in Clinical Practice
por: Miller, Eden M.
Publicado: (2020)

Flash CGM Is Associated With Reduced Diabetes Events and Hospitalizations in Insulin-Treated Type 2 Diabetes
por: Bergenstal, Richard M, et al.
Publicado: (2021)

Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin
por: Hinnen, Debbie A.
Publicado: (2015)

Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: Right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for noninsulin users
por: Polonsky, William H., et al.
Publicado: (2013)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
por: Kleefstra, Nanne, et al.
Publicado: (2009)

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
por: Heller, Simon, et al.
Publicado: (2023)

Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis
por: Carlson, Anders L, et al.
Publicado: (2022)

Continuous subcutaneous insulin infusion and flash glucose monitoring in diabetic hemiballism-hemichorea
por: Qiang, Wei, et al.
Publicado: (2020)

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023)

A Pilot Study to Assess Clinical Utility and User Experience of Professional Continuous Glucose Monitoring Among People With Type 2 Diabetes
por: Midyett, Kurt, et al.
Publicado: (2019)

A Text-Mining Analysis to Examine Dominant Sources of Online Information and Content on Continuous Glucose Monitors
por: Heitkemper, Elizabeth M., et al.
Publicado: (2023)

Adoption Barriers for Continuous Glucose Monitoring and Their Potential Reduction With a Fully Implanted System: Results From Patient Preference Surveys
por: Engler, Robert, et al.
Publicado: (2018)

Noninsulin pharmacological management of type 1 diabetes mellitus
por: Garg, Vishvas
Publicado: (2011)

Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes
por: Lingow, Sara E., et al.
Publicado: (2019)

Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin
por: Goldman, Jennifer D., et al.
Publicado: (2023)

Trace and toxic element patterns in nonsmoker patients with noninsulin-dependent diabetes mellitus, impaired glucose tolerance, and fasting glucose
por: Serdar, Muhittin A., et al.
Publicado: (2009)

Self-Monitoring of Blood Glucose in Noninsulin-Using Type 2 Diabetic Patients: It is time to face the evidence
por: Malanda, Uriëll L., et al.
Publicado: (2013)

'Continuous learning is contagious'
por: Hylton, Preetee
Publicado: (2021)

Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review
por: Purnell, Tanjala S., et al.
Publicado: (2014)

Proximal Predictors of Long-Term Discontinuance with Noninsulin Antihyperglycemic Agents
por: Stuart, Bruce C., et al.
Publicado: (2016)

Continuous Intravenous Milrinone Therapy in Pediatric Outpatients
por: Curley, Michelle, et al.
Publicado: (2017)

The continued importance of dental safeguarding during the pandemic
por: Foster, Mark
Publicado: (2021)

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
por: Skolnik, Neil, et al.
Publicado: (2018)

iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
por: Hinnen, Debbie, et al.
Publicado: (2018)

Ambulatory Glucose Profile Changes During Pregnancy in Women With Type 1 Diabetes Using Intermittently Scanned Continuous Glucose Monitoring Empowered by Personalized Education
por: Baretić, Maja, et al.
Publicado: (2023)

Comparison of the FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System and Point-of-Care Capillary Glucose Testing in Hospitalized Patients With Type 2 Diabetes Treated With Basal-Bolus Insulin Regimen
por: Galindo, Rodolfo J., et al.
Publicado: (2020)

Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19
por: Prosser, Barbara, et al.
Publicado: (2022)

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
por: Wysham, Carol H., et al.
Publicado: (2018)

Intensive Structured Self-Monitoring of Blood Glucose and Glycemic Control in Noninsulin-Treated Type 2 Diabetes: The PRISMA randomized trial
por: Bosi, Emanuele, et al.
Publicado: (2013)

Use of Noninsulin Anti Diabetics for Prevention and Treatment of Cancer- Narrative Review Article
por: RAANA, Sadaf, et al.
Publicado: (2015)

Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
por: King, Aaron, et al.
Publicado: (2023)

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin
por: Aleppo, Grazia, et al.
Publicado: (2021)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe, Shinya, et al.
Publicado: (2011)

Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review
por: Vettoretti, Martina, et al.
Publicado: (2019)

Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice
por: Blonde, Lawrence, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_el1gdsfo70t9fu6lt83d19ob0a